Saracatinib will be given orally at a dose of 125 milligrams once daily for 9 months. Saracatinib is provided as a pink tablet.

Pulmonary Lymphangioleiomyomatosis

Subjects will receive enough tablets for 90 days +/- 14 days at each visit. Subject will have visits every 90 days for drug accountability as well as safety and efficacy testing to include pulmonary function testing, laboratory testing to include liver and kidney profile, urine pregnancy testing at each visit, vital signs, physical examination - any medically significant changes from baseline visit will be recorded, all adverse events will be monitored until resolution.

saracatinib

Stanford University

Loyola Medical Center

Laboratory of Translational Research NHLBI

University of Cincinnati

Baylor College of Medicine - Ben Taub General Hospital

Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis

Tony Eissa

Principal Investigator

Baylor College of Medicine

Brigham and Women's Hospital

Loyola University

University of South Florida

National Institutes of Health (NIH)

Epilepsies, Partial

National Institutes of Health Clinical Center, 9000 Rockville Pike

Brain P-gp and Inflammation in People With Epilepsy

Positron Emission Tomography Measurement of Neuroinflammation in Focal Epilepsy

National Institute of Neurological Disorders and Stroke (NINDS)

threonine

seizures

threonine/seizures

Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis

Brain P-gp and Inflammation in People With Epilepsy

Täydellisin lääketieteellinen tietokanta tieteen tukemana